Archana Balakrishnan, MD

Clinical Interests

• Patient-physician communication
• Medical management of the acute care adult

Research Interests

• Frailty assessment

Educational Background

• Fellowship, Hospice and Palliative Medicine, Cooper University Hospital, Camden, NJ
• Residency, Internal Medicine, Cooper University Hospital, Camden, NJ
• Residency, Internal Medicine, Hahnemann University Hospital, Philadelphia, PA
• MD, Michigan State University, East Lansing, MI

Certifications

• Internal Medicine

Memberships

• American College of Physicians
• American Academy of Hospice & Palliative Medicine

Additional Publications

Kooragayala K, Butchy M, Lou, J, Balakrishnan A, Sandilos G, Kwiatt M, Giugliano D, McClane S. Impact on Frailty on Patient Outcomes after Hartmann’s Reveral: A NSQIP Analysis. The American Surgeon. January 2023.

Green, A., Puri, N., Kouch, M., Wolfe, Y., Balakrishnan, A., Abramian, O., Boujaoude, Z, Abouzgheib, W., (2022). Cryotherapy: A Safe Approach to Pulmonary Hemorrhage during VV-ECMO. Journal of Investigative Medicine High Impact Case Reports. January 2022.

Reap, L., McDonald, K., Balakrishnan, A., Vakhariya, C. (2019). Kasabach-Merritt-like phenomenon in a massive uterine leiomyoma resenting with chronic disseminated intravascular coagulation. Case Reports in Women’s Health 2020, Oct; e00262

Martinez-Chanza, N., Xie, W., Bilen, A., Dzimitrowicz, H., Burkart, J., Geynisman, D., Balakrishnan, A., Bowman, A., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, B., Bosse, D., Agarwal, N., McKay, R., Hsu, J., Shah, S., Tripathi, A., Lam, T., Rose, T., Carneiro, B., Vogelzang, N., Vaishampayan, U.,& Harshman, L. (2018). Cabozantinib in advanced non-clear cell renal carcinoma: a multicenter retrospective analysis. Lancet Oncology.

Assad, H., Barbat, B., Markosyan, M., Hukku, A., Balakrishnan, A., Flynn, J., Bloom R.E.. Contralateral prophylactic mastectomy, social economics and informed medical decision making. Journal of Clinical Oncology. 2018, May; 36(15): e12622

Martinez-Chanza, N., Xie, W., Bilen, A., Dzimitrowicz, H., Burkart, J., Geynisman, D., Balakrishnan, A., Bowman, A., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, B., Bosse, D., Agarwal, N., McKay, R., Hsu, J., Shah, S., Tripathi, A., Lam, T., Rose, T., Carneiro, B., Vogelzang, N., Vaishampayan, U.,& Harshman, L. (2018). Cabozantinib in advanced non-clear cell renal carcinoma: a multicenter retrospective analysis. Journal of Clinical Oncology 2018, May, 36(15) 4579-79

Balakrishnan, A., Vyas, D., Deshpande, K., & Vyas, A. (2016). Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer. World Journal Of Gastroenterology, 22(7), 2159–64

Liu, C., Widen, S. A., Williamson, K. A., Ratnapriya, R., Gerth-Kahlert, C., Rainger, J., Ramakrishna, A., Strachen, E., Manjunath, S., Balakrishnan, A., Floyd, JA., Li, T., Waskiewicz, A., Brooks, B., Lehmann, OJ., FitzPatrick, DR., & Swaroop, A. (2016). A secreted WNT-ligand-binding domain of FZD5 generated by a frameshift mutation causes autosomal dominant coloboma. Human Molecular Genetics, 25(7), 1382–1391.